The Spanish drug market has registered annual growth of about 8% since 2004, according to figures from IMS Health. Sales of drugs in Spain in 2007 increased 8.8% to a value of some 13.2 billion euros ($20.49 billion). Some slowing of growth is forecast for this year. New drug development has been focused in the oncology and biotechnology areas.
The oncology drug market grew 15.7% in Spain in 2007 with sales of around 1.1 billion euros, while the strongest sector was that of cardiovascular drugs with sales of 2.07 billion euros. Pfizer led the field with a market share of 6.5% followed by Sanofi-Aventis at 6.2%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze